Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer.

Fumiya Sugino,Keita Nakane,Makoto Kawase,Shota Ueda,Masayuki Tomioka,Yasumichi Takeuchi,Risa Tomioka-Inagawa,Toyohiro Yamada,Sanae Namiki, Naotaka Kumada,Shinichi Takeuchi,Kota Kawase,Daiki Kato,Manabu Takai,Koji Iinuma,Yuki Tobisawa,Takuya Koie

Life (Basel, Switzerland)（2023）

引用 0|浏览6

暂无评分

摘要

This study indicates that combining neoadjuvant LHRH antagonists and UFT followed by RARP may improve oncological outcomes in patients with high-risk PCa.

查看译文

关键词

high-risk prostate cancer, robot-assisted radical prostatectomy, neoadjuvant chemohormonal therapy, luteinizing hormone-releasing hormone antagonist, tegafur-uracil

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要